Aggregation control is among the most consequential quality challenges in monoclonal antibody development. For regulatory and CMC teams preparing a Biologics License Application, the agency's expectations around high molecular weight species and subvisible particles carry direct implications for specification-setting, stability program design, and ultimately the immunogenicity risk profile presented to reviewers.
This analysis examines how FDA frames aggregation as a patient-safety concern, what the agency expects in terms of specifications and analytical characterization methods, and the recurring deficiencies that appear in CDER CMC reviews of mAb BLAs — drawing on the ICH quality framework and publicly available review documents.
Want Rhizome's help on your own question? Try it for free.
How FDA approaches aggregation control for therapeutic monoclonal antibodies in BLA reviews
Aggregation is one of the quality attributes FDA scrutinizes most closely in a monoclonal antibody (mAb) Biologics License Application. High molecular weight species (HMWS) and subvisible particles are treated not as cosmetic stability findings but as attributes with a plausible link to immunogenicity and patient safety, and FDA reviewers repeatedly push sponsors to prove that their control strategy actually captures aggregate behavior across shelf life and use conditions. This overview summarizes how the agency frames the risk, what it expects in specifications and characterization, and the deficiencies it raises most often, drawing on CDER chemistry (CMC) reviews and the ICH quality framework that underpins them.
Why aggregation is a review priority: the immunogenicity link
FDA's core concern is that aggregates and particulates can drive an anti-drug antibody (ADA) response. Reviewers state this directly. In one mAb review, FDA noted that reporting subvisible and translucent material was acceptable during clinical trials, but that "when the BLA is submitted, an exact specification is needed," because "particulate matter and aggregates can cause immunogenicity" 158. In a meeting discussion for another antibody, FDA said subvisible particles "are still a concern as droplets often associate with proteins and can form protein complexes," and that the absence of protein in the particles could not be confirmed 156.
Because of this, aggregate-related attributes are routinely elevated in risk-ranking exercises. In a rituximab biosimilar review, FDA placed particles and aggregates in the analytical similarity package and ranked them by potential impact on "clinical efficacy, PD/PK, safety and immunogenicity," with non-spherical subvisible particles by micro-flow imaging (MFI) ranked as moderate risk 157. In a bevacizumab biosimilar review, MFI analysis of non-spherical particles was designated a higher-tier attribute "because of its potential to affect immunogenicity and safety" 166. The same risk-based logic, ranking attributes by their risk to "safety, efficacy, and immunogenicity," appears across biosimilar comparability reviews 167168.
The specification framework: SEC as the workhorse
Under ICH Q6B, aggregates fall within the "purity and impurities" framework for biotechnological products. Q6B defines aggregates as "dimers and higher multiples of the desired product," which are generally resolved from the monomer and quantitated by appropriate analytical procedures 87. A key conceptual distinction runs through the guideline: molecular variants formed during manufacture or storage that remain comparable to the desired product in activity, efficacy, and safety are "product-related substances" and are not treated as impurities, whereas variants with different properties are "product-related impurities" 899597. In practice, mAb aggregates are almost always treated as product-related impurities and controlled accordingly. Q6B also expects the manufacturer to define the pattern of size heterogeneity of the desired product and demonstrate its consistency with the lots used in preclinical and clinical studies 88.
Size-exclusion chromatography (SEC / SE-HPLC) is the workhorse release and stability method. FDA generally expects aggregates to be controlled either as percent monomer (with aggregates as the complementary impurity) or as explicitly quantified HMWS, with separate release and shelf-life acceptance criteria when the attribute can change on storage 1112. Concrete patterns from reviews:
- Purity or monomer content is tracked as a critical quality attribute "measured at both release and stability," with the specification considered appropriate when it stays above the level where potency or quality could be affected 125.
- A defined monomer acceptance criterion applied at both release and shelf life is a common form of SEC-type control, for example a monomer lower limit set for release and shelf-life 126.
- Where the method is designed to detect molecular-weight shifts, HMWS themselves become the readout monitored as product-related impurities through routine batch testing 17.
- FDA expects sponsors to set separate release and shelf-life limits for attributes expected to drift during storage, derived from stability data, historical batch data, and process variation 127.
A recurring FDA principle is that acceptance criteria must be clinically and manufacturing-qualified, not merely statistically derived from a handful of lots. In one review FDA objected that the clinical lot quality was "considerably superior to a lot that would satisfy the minimum conditions listed in the acceptance specification," and asked the sponsor to justify or revise the specification so it reflected the lots actually used in preclinical and clinical studies, one of the "two major considerations" being that future lots be equivalent in quality to the study lots 164.
Subvisible and visible particulate control
Particulate matter is controlled as a distinct, safety-linked attribute. FDA expects compendial subvisible particle testing by light obscuration (USP <787>/<788> for injections), reported as particle counts per container, with defined acceptance limits 45158. For more detailed particle characterization, especially morphology and non-spherical (often proteinaceous) particles, reviewers point to micro-flow imaging (MFI) 157. Visible particulates are addressed through 100% visual inspection and labeling language, with the recognition that some translucent proteinaceous particles may be inherent to a protein product 125. The through-line is that these particle attributes matter because they may reflect or contain aggregated protein, which ties back to the immunogenicity concern 156157158.
Characterization: orthogonal methods beyond SEC
FDA does not accept SEC as a standalone truth. Reviewers expect orthogonal methods to confirm that SEC is accurately measuring aggregate content and to characterize the nature of the species:
- Sedimentation velocity analytical ultracentrifugation (SV-AUC) is used as the primary orthogonal check on SE-HPLC. In an adalimumab review it was used to investigate purity, the main molecular species, and HMW variants, and showed comparable HMW levels, monomer levels, frictional ratio, and molecular weights 162. AUC is valued because it operates without a column matrix and can detect aggregate species SEC may miss 145.
- SEC coupled with multi-angle light scattering (SEC-MALS) is used to estimate the absolute molar mass of the monomer and higher oligomeric species and to characterize size variants independently of column calibration 160163.
- Dynamic light scattering (DLS) and asymmetric flow field-flow fractionation (AF4) are used to confirm size and, in one pegfilgrastim review, to compare the size profiles of different products 161.
- CE-SDS / SDS-PAGE under reducing and non-reducing conditions distinguishes covalent/disulfide-linked HMWS from non-covalent aggregates: non-reduced conditions reveal HMW species present with intact disulfides, while reduced conditions show whether those species resolve into subunits 22211112. FDA antibody guidance calls for SDS-PAGE run both with and without reducing agents as part of purity and molecular-integrity testing, including assessment of "aggregated, denatured or fragmented product" 1112.
Stability and comparability
For stability, ICH Q5C directs sponsors to use stability-indicating methods capable of detecting degradation changes on storage, explicitly listing aggregation among the relevant changes, and to base acceptable degradation limits on the analytical profiles of the batches used in preclinical and clinical studies 83. FDA reviews reinforce this by asking sponsors to build aggregate testing into post-approval stability protocols; in one avelumab review FDA asked the applicant to "include a test to assess aggregates in your post approval stability protocols for both DS and DP with equivalent criteria to those in your proposed specifications" 169.
For manufacturing changes and biosimilar development, ICH Q5E frames the comparability exercise: a suitably selected battery of analytical tests should detect relevant differences in quality attributes, including the purity/impurity profile, and the extent of study depends on the change, the availability of suitable techniques, and the relationship of the attributes to safety and efficacy 323334. FDA's comparability guidance for antibody products calls for side-by-side biochemical characterization of pre- and post-change lots using techniques such as SEC, reducing and non-reducing SDS-PAGE, and mass spectrometry, with molecular integrity explicitly covering aggregated, denatured, or fragmented product 341112.
Commonly cited deficiencies
The most instructive material is the pattern of concerns FDA raises in CMC reviews and information requests. Recurring themes:
1. SEC validated only on unstressed release lots. For tbo-filgrastim (Granix), FDA noted the SE-HPLC method measured monomers, dimers, and HMW species but had been validated only with unstressed release samples, where aggregate levels are low. Because different aggregates can accumulate over time, FDA asked for data showing SEC gives an accurate measure of aggregate content "through the product's shelf life and conditions of use," or an alternative method, suggesting stress studies (temperature, agitation, light) with comparison to AUC 145146.
2. Inadequate method performance for HMW species. For pegloticase (Krystexxa), FDA found SEC-HPLC recovery problems (dimers 75 to 85%, high molecular weight forms 49 to 55%) and directed the sponsor to "improve the accuracy of the SEC-HPLC method for detection of high molecular weight species" 148. For sebelipase alfa (Kanuma), FDA did not accept an SDS-PAGE approach for HMW product-related species and asked for an improved SDS-PAGE or another purity test with greater sensitivity and precision 149150151152.
3. Aggregate control requires orthogonal confirmation. For Xiaflex, FDA accepted SEC-HPLC only as an orthogonal method and proposed a post-marketing commitment to confirm SEC accuracy for detecting aggregates using stress samples and orthogonal methods such as AUC or field-flow fractionation, emphasizing quantitative detection of HMW aggregates 171178.
4. Specifications too broad or not clinically justified. For canakinumab, FDA said the proposed SEC limits should be tightened, adding a monomer limit and tightening the drug substance and drug product aggregate limits to reflect batch experience 182. For pegloticase, FDA said the proposed limits for higher/lower molecular weight species "appear to be very broad" and must be based on process capability, manufacturing experience, and clinical experience, and recommended an orthogonal RP-HPLC assay 189. For a trastuzumab biosimilar, FDA said release and end-of-shelf-life specifications must be sufficiently narrow and based on clinical and manufacturing experience, so that lots released near the limit do not later fall out of specification 181188.
5. Quantitative aggregate criteria expected by late-stage development. For benralizumab (Fasenra), FDA recommended quantitative release criteria for "% aggregates and fragments detected by HPSEC" 184.
6. Unclear characterization of the aggregate species. For aflibercept (Eylea), FDA flagged apparent HMW bands in reduced SDS-PAGE and found the sponsor's claim that stress-induced aggregates were reversible and non-covalent to be inconsistent with the data, asking for clarification and supporting analyses of the nature of the aggregates under stress 172173174176179.
Practical takeaways for a BLA sponsor
Read together, FDA's expectations for mAb aggregation control are consistent: control aggregates by SEC with quantitative, clinically qualified release and shelf-life specifications; prove the SEC method is stability-indicating across relevant stress and storage conditions rather than validated only on release lots; support it with orthogonal characterization (SV-AUC, SEC-MALS, DLS/AF4, and reduced/non-reduced CE-SDS to distinguish covalent from non-covalent species); control subvisible and visible particulates by compendial and imaging methods; and justify every acceptance limit against process capability and the quality of the nonclinical and clinical lots. The unifying rationale, stated plainly in the reviews, is that aggregates and particulates can cause immunogenicity, so the burden is on the sponsor to demonstrate that the control strategy meaningfully bounds that risk 145148157158164182189.